尽管炎症性肠病有先进的治疗方法，但疾病负担持续存在：来自希腊的一项现实世界患者报告调查
Persistent disease burden despite advanced therapies in inflammatory bowel disease: a real-world patient-reported survey from Greece.
摘要(中文译文)
尽管治疗已取得进展，炎症性肠病（IBD）仍是一种终身致残性疾病，负担沉重。本研究旨在调查希腊接受先进治疗的IBD患者的疾病负担和未满足需求。2023年10月至2024年1月期间，希腊克罗恩病和溃疡性结肠炎患者协会（HELLESCC）中接受先进治疗的成年CD和UC患者完成了一份结构化自报问卷。调查收集了社会人口学特征、吸烟状况、合并症、疾病活动度、疾病特征、当前用药及患者报告结局（PROs；短版炎症性肠病问卷[SIBDQ]、工作生产力与活动受损量表[WPAI]、患者健康问卷-9[PHQ-9]、治疗满意度和依从性）等数据。采用单因素和多因素logistic回归分析确定相关因素。在287例接受先进治疗的IBD患者（201例CD，86例UC）中，57.1%存在活动性疾病。总体而言，76.4%报告生活质量受损，30.3%报告工作生产力损失，38.4%报告活动受损，近半数表现出中度至重度抑郁症状。值得注意的是，39.1%对先进治疗表示不满意，10.9%报告依从性降低。除依从性外，CD与UC患者在各项PROs上未观察到显著差异。较高的疾病活动度始终与较差的生活质量、更大的工作受损、更多的抑郁症状及较低的治疗满意度相关。尽管接受了先进治疗，希腊患者的IBD负担仍然沉重。相当比例的患者经历生活质量差、工作受损增加、显著抑郁症状及持续性疾病活动。十分之四的患者报告明显的治疗不满意，凸显了对更有效管理策略的未满足需求。
Abstract
Despite therapeutic advances, inflammatory bowel disease (IBD) remains a lifelong debilitating disorder with substantial burden. The study aimed to investigate disease burden and unmet needs in IBD patients receiving advanced therapies in Greece. Between October 2023 and January 2024, adult CD and UC patients who were members of Hellenic Society of Crohn's disease's and Ulcerative Colitis' patients (HELLESCC) and receiving advanced therapies completed a structured self-reported questionnaire. The survey collected data on sociodemographic characteristics, smoking status, comorbidities, disease activity, disease characteristics, current medications, and patient-reported outcomes (PROs; Short Inflammatory Bowel Disease Questionnaire [SIBDQ], Work Productivity and Activity Impairment [WPAI], Patient Health Questionnaire-9 [PHQ-9], treatment satisfaction and adherence). Both univariate and multivariate logistic regression analyses were performed to determine associated factors. Among 287 patients with IBD (201 with CD, 86 with UC) receiving advanced therapies, 57.1% had active disease. Overall, 76.4% reported impaired QoL, 30.3% work productivity loss, and 38.4% activity impairment, while nearly half exhibited moderate-to-severe depressive symptoms. Notably, 39.1% expressed dissatisfaction with their advanced therapy, while 10.9% reported reduced adherence. No significant differences were observed between CD and UC patients across PROs, except for adherence. Higher disease activity was consistently associated with worse QoL, greater work impairment, increased depressive symptoms, and lower treatment satisfaction. Despite advanced therapies, IBD burden remains substantial among Greek patients. A considerable proportion experience poor QoL, increased work impairment, significant depressive symptoms, and persistent disease activity. Marked treatment dissatisfaction, reported by four out of ten patients, highlights an unmet need for more effective management strategies.
如何引用
AMA
Charalampos Tzanetakos, Vasiliki-Rafaela Vakouftsi, George Mavridoglou, Andriani Angelopoulou, George Gourzoulidis. Persistent disease burden despite advanced therapies in inflammatory bowel disease: a real-world patient-reported survey from Greece.. Frontiers in immunology. 2026; doi:10.3389/fimmu.2026.1866461.
APA
Charalampos Tzanetakos, Vasiliki-Rafaela Vakouftsi, George Mavridoglou, Andriani Angelopoulou, George Gourzoulidis (2026). Persistent disease burden despite advanced therapies in inflammatory bowel disease: a real-world patient-reported survey from Greece.. Frontiers in immunology. https://doi.org/10.3389/fimmu.2026.1866461
GB/T 7714
Charalampos Tzanetakos, Vasiliki-Rafaela Vakouftsi, George Mavridoglou, Andriani Angelopoulou, George Gourzoulidis. Persistent disease burden despite advanced therapies in inflammatory bowel disease: a real-world patient-reported survey from Greece.[J]. Frontiers in immunology, 2026 doi:10.3389/fimmu.2026.1866461.
在 PubMed增强版 阅读全文
翻译全文 · AI 文献问答 · PDF 原文下载 · 引用导出